Leishmaniasis is a tropical disease caused by Leishmania parasites and currently has no licensed vaccines. We developed a dermotropic Leishmania major centrin gene-deleted strain (LmCen) as a live attenuated vaccine. Recent studies have shown that type I interferons (IFNs) play important roles in immunity to parasitic and viral pathogens.
View Article and Find Full Text PDFCentrin1 gene deleted Leishmania donovani parasite (LdCen1) was developed and extensively tested experimentally as an intracellular stage-specific attenuated and immunoprotective live parasite vaccine candidate ex vivo using human PBMCs and in vivo in animals. Here we report manufacturing and pre-clinical evaluation of current Good-Laboratory Practice (cGLP) grade LdCen1 parasites, as a prerequisite before proceeding with clinical trials. We screened three batches of LdCen1 parasites manufactured in bioreactors under cGLP conditions, for their consistency in genetic stability, attenuation, and safety.
View Article and Find Full Text PDFImmunization with various species lacking induces robust immunity against a homologous and heterologous virulent challenge, making mutants a putative candidate for a leishmaniasis vaccine. Centrin is a calcium-binding cytoskeletal protein involved in centrosome duplication in higher eukaryotes and spp. lacking centrin are unable to replicate and are non-pathogenic.
View Article and Find Full Text PDFViolet-blue light of 405 nm in the visible spectrum at a dose of 270 J/cm alone has been shown to be an effective microbicidal tool for inactivating several bacteria, HIV-1, and in ex vivo plasma and platelets. Unlike chemical- and ultraviolet (UV)-based pathogen inactivation methods for plasma and platelet safety, 405 nm light is shown to be less toxic to host cells at light doses that are microbicidal. In this report, we evaluated the parasiticidal activity of a 405 nm light treatment on platelets spiked with the parasite.
View Article and Find Full Text PDFCutaneous leishmaniasis (CL) is characterized by extensive skin lesions, which are usually painless despite being associated with extensive inflammation. The molecular mechanisms responsible for this analgesia have not been identified. Through untargeted metabolomics, we found enriched anti-nociceptive metabolic pathways in -infected mice.
View Article and Find Full Text PDF